Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

(2016) S. Dubois et al.   CLINICAL CANCER RESEARCH

Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling

(2015) Ji Yuan et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

CRM1 as a new therapeutic target for non-Hodgkin lymphoma

(2015) Xiaohong Han et al.   LEUKEMIA RESEARCH

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma

(2015) Linka Xie et al.   Oncotarget

Rgb: a scriptable genome browser for R

(2014) Sylvain Mareschal et al.   BIOINFORMATICS

Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL

(2014) J. Bond et al.   BLOOD

Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

(2014) Kieron Dunleavy et al.   BLOOD

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells

(2014) J. Reichel et al.   BLOOD

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma

(2014) Mariko Yoshimura et al.   CANCER SCIENCE

Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling

(2014) Irfana Muqbil et al.   CURRENT PHARMACEUTICAL DESIGN

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

A general framework for estimating the relative pathogenicity of human genetic variants

(2014) Martin Kircher et al.   NATURE GENETICS

Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma

(2014) Jay Gunawardana et al.   NATURE GENETICS

Genomic and molecular characterization of esophageal squamous cell carcinoma

(2014) De-Chen Lin et al.   NATURE GENETICS

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting the Nuclear Transport Machinery by Rational Drug Design

(2013) Lei Mao et al.   CURRENT PHARMACEUTICAL DESIGN

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

(2013) Richard Delarue et al.   LANCET ONCOLOGY

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

(2013) S Jeromin et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)

(2012) N. Ketterer et al.   ANNALS OF ONCOLOGY

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?

(2012) Kieron Dunleavy et al.   Current Hematologic Malignancy Reports

The molecular pathogenesis of primary mediastinal large B-cell lymphoma

(2011) C. Steidl et al.   BLOOD

Jetset: selecting the optimal microarray probe set to represent a gene

(2011) Qiyuan Li et al.   BMC BIOINFORMATICS

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

(2011) O. Fitoussi et al.   HAEMATOLOGICA

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

(2011) Christian Récher et al.   LANCET

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

(2011) Frédéric Peyrade et al.   LANCET ONCOLOGY

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma

(2009) O. Ritz et al.   BLOOD

Structural basis for leucine-rich nuclear export signal recognition by CRM1

(2009) Xiuhua Dong et al.   NATURE

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA